Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Lit...
September 25 2017 - 8:05AM
-- Bioreactors Now Online and Able to Meet Needs
of Current and Future Clients --
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine
Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced
the successful installation and validation of two Mobius®
2,000-liter single-use bioreactors from MilliporeSigma in Avid’s
Myford clinical and commercial manufacturing facility. The
bioreactors are officially online and able to accommodate the
growing demand for larger scale single-use bioreactors from current
and future Avid clients. Avid has already secured customer
commitments for a portion of the manufacturing capacity associated
with the new bioreactors.
“We have been working diligently on the
installation and validation of these new 2,000-liter bioreactors
and are excited to now be in a position to launch the manufacturing
activities that this state-of-the-art equipment enables. This
enhancement of our capabilities is just the latest step in our
ongoing efforts to expand and diversify our customer base,” said
Roger Lias, Ph.D., president of Avid Bioservices. “Importantly,
based on the modular design of our Myford facility, we have the
ability to install one additional 2,000-liter bioreactor, allowing
us to further accelerate the growth of the
business.”
The newly installed 2,000-liter single-use
bioreactors offer a range of important manufacturing advantages and
efficiencies as compared to other equipment. Traditionally,
biopharmaceutical companies used large stainless steel vessels in
multi-story buildings, requiring substantial investment and
rigorous setup. With single-use disposable equipment, customers get
improved batch turnaround times, reduced risk of product
cross-contamination, decreased capital costs and have less
equipment to clean. Single-use technology helps accelerate
customers’ molecules to market, improve productivity, and ensure
supply continuity.
“MilliporeSigma’s Mobius® 2,000-liter single-use
bioreactors are easy to use and play an integral role in Avid’s
goal toward having a fully disposable biomanufacturing process,”
said Andrew Bulpin, Head of Process Solutions at MilliporeSigma.
“We look forward to continuing to work with companies around the
world to bring their molecules to market and accelerate production
of critical medicines.”
The 42,000 square foot Myford facility is
designed with cutting-edge, single-use equipment to accommodate a
fully disposable biomanufacturing process. A wide range of
innovative features are incorporated into this new facility
including monolithic modular clean rooms, dedicated support
utilities for each key processing area, and the industry’s most
advanced single-use production systems and flexible
solutions. Uni-directional process flows separate personnel
and materials and provide assurance that the design meets the most
stringent regulatory requirements for commercial biologics API
manufacturing.
About Avid Bioservices, Inc.Avid Bioservices, a
wholly owned subsidiary of Peregrine Pharmaceuticals, provides a
comprehensive range of process development, high quality cGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 20 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, including 12
years of commercial manufacturing for products sold in 18
countries, Avid's services include cGMP clinical and commercial
product manufacturing, purification, bulk packaging, lot release
and stability testing, regulatory strategy, submission and support.
The company also provides a variety of process development
activities, including cell line development and optimization, cell
culture and feed optimization, analytical methods development,
qualification/validation, process and product characterization. For
more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering
high quality pharmaceutical products through its contract
development and manufacturing organization (CDMO) services and
through advancing and licensing its investigational immunotherapy
and related products. Peregrine's in-house CDMO services,
including cGMP manufacturing and development capabilities, are
provided through its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. The
company is also working to evaluate its lead immunotherapy
candidate, bavituximab, in combination with immune stimulating
therapies for the treatment of various cancers, and developing its
proprietary exosome technology for the detection and monitoring of
cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024